SkinMedica(R) CEO, Mary Fisher, Joins ZELTIQ(R) Aesthetics Board Of Directors

PLEASANTON, Calif., Sept. 19, 2012 (GLOBE NEWSWIRE) -- ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced Mary Fisher has joined its Board of Directors.

"We are very pleased that Mary has agreed to join our Board of Directors. Her familiarity with and success and deep relationships in the aesthetic space will bring incremental and valuable domain expertise to the Company," said Mark Foley, President and Chief Executive Officer of ZELTIQ. "Due to our overlapping customer base, we believe that Mary has a good feel as to what motivates both our physicians and patient customers."

"I am excited to be joining ZELTIQ Aesthetics at this important time in the Company's growth cycle," said Mary Fisher, SkinMedica Chief Executive Officer. "I have been aware of ZELTIQ's success in the marketplace and look forward to partnering with the management team to help them reach their growth objectives." 

Ms. Fisher joined SkinMedica as Chief Executive Officer, and as a member of the Board of Directors, in April 2008. Her previous experience includes more than 25 years in the pharmaceutical and biotechnology industries. Most recently, she was Chief Operating Officer of Acorda Therapeutics, a CNS company, with responsibility for corporate strategy and business development, financial planning, sales and marketing, and manufacturing. Previously, Ms. Fisher was Vice President, Strategic Healthcare and Commercial Operations for Cephalon, with responsibility for product planning and marketing, managed care sales, and manufacturing. Her earlier experience includes positions at Immunex and Boehringer Ingelheim. She is also a member of the Board of Neuroscience Nursing Foundation.

About ZELTIQ Aesthetics, Inc.

ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise. 
CONTACT: MEDIA CONTACT:         Shari Gold         GOLD PR for ZELTIQ         714-251-0375                  INVESTOR RELATIONS:         Mark Foley         ZELTIQ, President and CEO         925-474-2500                  Nick Laudico / Amy Glynn         The Ruth Group for ZELTIQ         646-536-7030 / 7023

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value